Headaches are among the most common neurological complaints, affecting a vast proportion of the global population. While many headaches are benign and self-limiting, some represent severe, debilitating conditions that significantly impair quality of life and productivity. For pain medicine providers, a comprehensive understanding of headache classification, diagnostic criteria, and evidence-based management strategies for primary headache disorders (those not caused by another condition) is essential. This article will review the three most prevalent primary headache types: tension-type headache, migraine, and cluster headache.

I. Tension-Type Headache (TTH)

TTH is the most common type of primary headache, characterized by mild to moderate pain that is often described as a tight band around the head.

• Epidemiology: Affects up to 80% of the population at some point in their lives.
• Pathophysiology: Largely attributed to pericranial myofascial pain and central sensitization. Psychological stress, anxiety, and depression are significant contributing factors.
• Diagnostic Criteria (ICHD-3):
  • Headache lasting from 30 minutes to 7 days.
  • At least two of the following characteristics:
    • Bilateral location.
    • Pressing or tightening (non-pulsating) quality.
    • Mild or moderate intensity.
    • Not aggravated by routine physical activity.
  • Both of the following:
    • No nausea or vomiting.
    • No more than one of photophobia or phonophobia.
  • Not better accounted for by another ICHD-3 diagnosis.
• Management:
  • Acute Treatment:
    • First-line: Simple analgesics like acetaminophen (paracetamol) or NSAIDs (ibuprofen, naproxen).
    • Avoid frequent use to prevent medication overuse headache (MOH).
  • Preventive Treatment (for chronic TTH, >15 days/month for >3 months):
    • Tricyclic Antidepressants (TCAs): Amitriptyline is considered first-line, even in non-depressed patients, due to its analgesic and muscle-relaxant properties.
    • Stress management, biofeedback, physical therapy, and acupuncture.

II. Migraine

Migraine is a debilitating neurological disorder characterized by recurrent episodes of moderate to severe headache, often accompanied by autonomic symptoms.

• Epidemiology: Affects approximately 12-15% of the general population, more common in women.
• Pathophysiology: A complex neurobiological disorder involving central nervous system hyperexcitability, cortical spreading depression (CSD), and activation of the trigeminal pain pathway (trigeminovascular system). Neurotransmitters like serotonin and calcitonin gene-related peptide (CGRP) play crucial roles.
• Phases of a Migraine Attack (not all patients experience all phases):
  1. Prodrome (Pre-headache): Occurs hours to days before the headache. Symptoms include fatigue, mood changes, neck stiffness, yawning, food cravings.
  2. Aura: Occurs in ~25% of migraineurs, usually before the headache. Most commonly visual (e.g., scintillating scotomas, zigzag lines), but can be sensory, motor, or speech-related. Lasts 5-60 minutes.
  3. Headache Phase: Moderate to severe, unilateral (often but not always), pulsating pain. Aggravated by physical activity, accompanied by nausea/vomiting, photophobia, phonophobia, and osmophobia. Lasts 4-72 hours.
  4. Postdrome (Post-headache): “Migraine hangover” with fatigue, difficulty concentrating, neck stiffness, or residual pain.
• Diagnostic Criteria (ICHD-3 for Migraine without Aura):
  • At least 5 attacks fulfilling criteria 2-4:
  • Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated).
  • Headache has at least two of the following:
    • Unilateral location.
    • Pulsating quality.
    • Moderate or severe pain intensity.
    • Aggravation by, or causing avoidance of, routine physical activity.
  • During headache, at least one of the following:
    • Nausea and/or vomiting.
    • Photophobia and phonophobia.
  • Not better accounted for by another ICHD-3 diagnosis.
• Management:
  • Acute (Abortive) Treatment:
    • Non-specific: NSAIDs, acetaminophen, antiemetics.
    • Specific:
      • Triptans (serotonin 5-HT1B/1D agonists): Sumatriptan, zolmitriptan, etc. Potent vasoconstrictors; contraindicated in patients with cardiovascular disease.
      • CGRP receptor antagonists (gepants): Ubrogepant, rimegepant. Newer class, effective without vasoconstrictive effects.
      • Ditans (5-HT1F agonists): Lasmiditan. Also effective without vasoconstriction, but can cause CNS depression.
      • Ergot derivatives (e.g., Dihydroergotamine): Less commonly used due to side effect profile.
  • Preventive Treatment (for frequent or disabling migraines, typically >4 days/month):
    • Beta-blockers: Propranolol, metoprolol.
    • Anticonvulsants: Topiramate, valproic acid.
    • Tricyclic Antidepressants: Amitriptyline.
    • CGRP monoclonal antibodies (mAbs): Erenumab, fremanezumab, galcanezumab, eptinezumab. Highly effective, well-tolerated agents that block CGRP or its receptor.
    • OnabotulinumtoxinA (Botox): For chronic migraine (>15 headache days/month).

III. Cluster Headache

Cluster headache is a rare but excruciatingly severe primary headache, often called “suicide headache” due to its intensity. It belongs to the trigeminal autonomic cephalalgias (TACs).

• Epidemiology: Affects ~0.1% of the population, more common in men (3:1 ratio). Occurs in “clusters” of attacks over weeks/months, followed by remission.
• Pathophysiology: Involves the hypothalamus (circadian rhythm disruption) and activation of the trigeminal autonomic reflex pathway.
• Diagnostic Criteria (ICHD-3):
  • At least 5 attacks fulfilling criteria 2-4:
  • Severe or very severe unilateral orbital, supraorbital, or temporal pain lasting 15-180 minutes (when untreated).
  • Accompanied by at least one of the following ipsilateral (same side) autonomic symptoms:
    • Conjunctival injection and/or lacrimation (red eye, tearing).
    • Nasal congestion and/or rhinorrhea (stuffy or runny nose).
    • Eyelid edema.
    • Forehead and facial sweating.
    • Miosis and/or ptosis (pupil constriction, drooping eyelid).
  • And/or a sense of restlessness or agitation.
  • Attacks occur at a frequency between one every other day and 8 per day.
  • Not better accounted for by another ICHD-3 diagnosis.
• Management:
  • Acute (Abortive) Treatment:
    • Oxygen: 100% oxygen at 12-15 L/min via a non-rebreather mask for 15-20 minutes is first-line.
    • Subcutaneous Triptans: Sumatriptan (6 mg SC) provides rapid and effective relief. Oral triptans are too slow.
  • Preventive Treatment (initiated at the start of a cluster period):
    • First-line: Verapamil (calcium channel blocker). Requires ECG monitoring due to cardiac side effects.
    • Other options: Lithium, corticosteroids (short course to bridge until other preventives take effect), topiramate.
    • Greater Occipital Nerve (GON) Block: Can be very effective.

Conclusion

Accurate diagnosis and appropriate management of primary headache disorders are crucial for improving patient quality of life. While tension-type headaches respond to simple analgesics and lifestyle modifications, migraine and cluster headaches require specific acute abortive therapies and, often, long-term preventive strategies. A thorough history, adherence to ICHD-3 diagnostic criteria, and a nuanced understanding of pharmacologic and interventional options empower pain medicine providers to effectively manage these challenging conditions.